Target intelligence / Profile preview

ELOVL2 antisense RNA 1 (non-protein coding) (ELOVL2-AS1)

Target: ELOVL2-AS1
Molecular classification: Long non-coding RNA (lncRNA), Natural antisense transcript (ncNAT), Enhancer RNA (eRNA)[1][3][4][6]

Overview

ELOVL2 antisense RNA 1 (ELOVL2-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the coding region of the ELOVL2 gene on chromosome 6. It functions as an enhancer RNA (eRNA) and natural antisense transcript, playing an important regulatory role in breast cancer biology—particularly in controlling the migration of triple negative breast cancer (TNBC) cells, regulating cilia-related genes, and modulating drug resistance to tamoxifen. ELOVL2-AS1 has been identified as downregulated in aggressive breast cancer subtypes, and its re-expression can inhibit cancer cell migration and reverse tamoxifen resistance, likely through both transcriptional regulation of ELOVL2 and effects on associated signaling pathways. ELOVL2-AS1 is emerging as a biomarker for breast cancer subtype classification, prognosis, and therapeutic responsiveness, but is not currently a direct therapeutic target[1][3][4][6][7].

Other names: ELOVL2-AS1ELOVL2 antisense RNA 1ELOVL2 antisense RNA 1 (non-protein coding)ENSG00000230314NCBI Gene 100506409HGNC:44156[7]

Mechanism of action

No current drugs directly target ELOVL2-AS1; however, modulation of ELOVL2-AS1 expression affects sensitivity to tamoxifen in breast cancer cells, primarily by influencing ELOVL2/PUFA metabolism, as well as regulation of miRNA sponging (e.g., miR-1233-3p) and epigenetic changes[1][4]

Biological functions

Regulation of ELOVL2 gene expression[1][4]Regulation of cell migration, particularly in triple negative breast cancer (TNBC)[1][6]Regulation of drug resistance, including tamoxifen resistance in breast cancer[1][4]Participation in cilia organization and motile cilium assembly through co-expressed gene networks[1]Regulation of signal transduction pathways including PI3K/AKT and Hedgehog signaling[1]

Disease associations

Breast cancer (especially triple negative breast cancer and hormone therapy resistance subtypes)[1][4][6]Cancer drug resistance (tamoxifen resistance)[4]

Safety considerations

None specifically reported for therapeutic targeting, as ELOVL2-AS1 is currently a biomarker and research molecule rather than a drug target[1][4]

Interacting drugs

Tamoxifen (indirect relationship via modulation of resistance mechanisms in breast cancer, no direct small molecule targeting known)[4]

Biomarkers

ELOVL2-AS1 expression as a diagnostic and prognostic marker for breast cancer subtype differentiation and tamoxifen resistance[1][4][6]

Beyond the preview

Go deeper on ELOVL2 antisense RNA 1 (non-protein coding) (ELOVL2-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELOVL2 antisense RNA 1 (non-protein coding) (ELOVL2-AS1).

Explore the full profile